Effectiveness and Safety of Therapy Based on Attenuated Arsenic Trioxide Plus Low Doses of All-trans Retinoic Acid as Remission Induction Therapy in Patients With Acute Promyelocytic Leukemia Phase 1/2 Clinical Trial
Latest Information Update: 31 Oct 2022
At a glance
- Drugs Arsenic trioxide (Primary) ; Tretinoin (Primary)
- Indications Acute promyelocytic leukaemia
- Focus Adverse reactions
Most Recent Events
- 17 Aug 2022 New trial record